

Safety of Baricitinib under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-case Post-marketing Surveillance and Spontaneous Reports (Interim report)

Hiroaki Matsuno¹, Tatsuya Atsumi², Shuji Takei³, Naoto Tamura⁴, Masayoshi Harigai⁵, Takao Fujii⁶, Shigeki Momohara⁷, Yuko Takahashi⁸, Nobuhiro Narii⁸, Naoto Tsujimoto⁸, Atsushi Nishikawa⁸, Taeko Ishii⁸, Kazuhiko Yamamoto⁹, Masataka Kuwana¹⁰, Michiaki Takagi¹¹

¹ Matsuno Clinic for Rheumatic Diseases

² Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University

³ Department of Pediatrics, Graduate School of Medical and Dental Science, Kagoshima University

⁴ Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine

⁵ Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Department of Rheumatology, Tokyo Women's Medical University

⁶ Department of Rheumatology and Clinical Immunology, Wakayama Medical University

⁷ Hakkeikai Incorporated Medical Institution, Kusanagi Seikei Clinic

⁸ Eli Lilly Japan K.K.

⁹ RIKEN Center for Integrative Medical Sciences

¹⁰ Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine

¹¹ Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine